Lineage Cell (LCTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$13.1M

Revenue (quarter)

$1.1M

Revenue growth (year over year)

−61.34%

Gross profit (trailing twelve months)

$13.0M

Gross margin

99.46%

Net income (trailing twelve months)

−$32.1M

Net income (quarter)

$1.5M

Net income growth (year over year)

+105.08%

Net margin

−245.39%

Return on equity

−59.03%

EPS (trailing twelve months)

−$0.14

Book value per share

$0.24

P/E (trailing twelve months)

—

Price to book

4.03

Debt to assets

43.70%

Payout ratio

—

Dividend yield

—

Company profile

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

• Is Lineage Cell (LCTX) profitable?

  No. Lineage Cell reported a net loss of $32.1M over the trailing twelve months.

• How much revenue does Lineage Cell (LCTX) make?

  Lineage Cell generated $13.1M in revenue over the trailing twelve months, down 61.34% year over year.

• How do I buy stock in Lineage Cell (LCTX)?

  LCTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.